covid
Buscar en
Endocrinología y Nutrición
Toda la web
Inicio Endocrinología y Nutrición Los productos de Amadori como mediadores de disfunción endotelial en la diabete...
Información de la revista
Vol. 51. Núm. 9.
Páginas 497-505 (noviembre 2004)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 51. Núm. 9.
Páginas 497-505 (noviembre 2004)
Acceso a texto completo
Los productos de Amadori como mediadores de disfunción endotelial en la diabetes mellitus
Amadori Products As Mediators Of Endothelial Dysfunction In Diabetes Mellitus
Visitas
16921
C.F. Sáncheza,*, C. Peiróa, L. Rodríguezb
a Departamento de Farmacología y Terapéutica. Facultad de Medicina. Universidad Autónoma de Madrid. Madrid
b Unidad de Investigación y Servicio de Geriatría. Hospital Universitario de Getafe. Getafe. Madrid. España
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

Vascular complications are the main cause of morbidity and mortality in diabetes mellitus. Endothelial dysfunction is the first link in the chain of physiopathological mechanisms leading to diabetic vasculopathy, both in large blood vessels (macroangiopathy) and small vessels (microangiopathy). Endothelial dysfunction (reduction in endothelial-dependent vasodilator response with or without an increase in vasoconstrictor responses) is associated with the maintenance of sustained hyperglycemia and an increase in oxidative stress in diabetes. Several mechanisms that might increase levels of reactive oxygen species and produce alterations in endothelial function have been studied. In this context, it has been proposed that hyperglycemia per se is able to produce this effect. However, most researchers suggest that the sustained increase in plasma glucose levels modifies different enzyme pathways, which in turn cause an increase oxidative stress and eventually endothelial dysfunction. Thus, enzymes such as aldose-reductase, protein kinase-C, and poly(ADP-ribose) polymerase, as well as endothelin receptors, among other mechanisms, have been implicated. In addition, nonenzymatic mechanisms, such as protein glycosylation, as a source of reactive oxygen species, with special attention paid to glycosylation end products, the socalled advanced glycosylation end products, have been proposed. However, for several years our group has maintained the hypothesis that early and intermediate glycosylation products (Amadori products) are able to release reactive oxygen species and may play an important role in the development of endothelial dysfunction and, eventually, diabetic vasculopathy.

Key words:
Diabetes mellitus
Endothelial dysfunction
Glycosylated proteins
Reactive oxygen species

Las complicaciones vasculares son la primera causa de morbimortalidad en la diabetes mellitus. La disfunción endotelial es el primer eslabón en la cadena de mecanismos fisiopatológicos que conducen a la vasculopatía diabética, tanto en vasos de conductancia (macroangiopatía) como de resistencia (microangiopatía). La disfunción endotelial (la reducción de las respuestas vasodilatadoras dependientes de endotelio, con o sin aumento de las respuestas vasoconstrictoras) es un fenómeno que se asocia con el mantenimiento de hiperglucemias sostenidas y el incremento del estrés oxidativo de la diabetes. Se han estudiado múltiples mecanismos que pueden aumentar los valores de especies reactivas de oxígeno y producir alteraciones de la función endotelial. En este sentido, se ha propuesto que la propia hiperglucemia per se es capaz de producir este efecto. Sin embargo, la mayor parte de los investigadores manifiesta que el aumento sostenido de los valores plasmáticos de glucosa modifica diferentes vías enzimáticas que, a su vez, originan un incremento del estrés oxidativo y eventualmente disfunción endotelial. Así, se han implicado enzimas como la aldosa-reductasa, la proteincinasa C, la polimerasa poli(ADP-ribosa), así como los receptores de endotelina, entre otros mecanismos. También se han propuesto mecanismos no enzimáticos, como la glucosilación de proteínas, como fuente de especies reactivas de oxígeno, con especial atención a los productos finales del proceso de glucosilación, los denominados productos terminales de glucosilación avanzada. Sin embargo, nuestro grupo mantiene desde hace años la hipótesis de que los productos tempranos e intermedios del proceso de glucosilación proteínica (los productos de Amadori) son capaces de liberar especies reactivas de oxígeno y pueden tener un papel relevante en el desarrollo de la disfunción endotelial y, eventualmente, de la vasculopatía diabética.

Palabras clave:
Diabetes mellitus
Disfunción endotelial
Proteínas glucosiladas
Especies reactivas de oxígeno
El Texto completo está disponible en PDF
Biblografía
[1.]
Z.B. Fortes, J.G. Leme, R. Scivoletto.
Vascular reactivity in diabetes mellitus: role of the endothelial cells.
Br J Pharmacol, 79 (1983), pp. 771-781
[2.]
I. Saénz de Tejada, I. Goldstein, K. Azadzoi, R. Krane, R.A. Cohen.
Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence.
N Engl J Med, 320 (1989), pp. 537-544
[3.]
A. Calver, J. Collier, P. Vallance.
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes.
J Clin Invest, 90 (1992), pp. 2548-2554
[4.]
M.T. Johnstone, S.J. Creager, K.M. Scales, A Cusco J, B.K. Lee, M.A. Creager.
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Circulation, 88 (1993), pp. 2510-2516
[5.]
G.E. McVeigh, G.M. Brennan, G.D. Johnston, B.J. McDermott, I.T. McGrath, W.R. Henry.
Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulindependent) diabetes mellitus.
Diabetologia, 35 (1992), pp. 771-776
[6.]
C. Yabe-Nishimura.
Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.
Pharmacol Rev, 50 (1998), pp. 21-31
[7.]
I. Idris, S. Gray, R. Donnelly.
Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes.
Diabetologia, 44 (2001), pp. 659-673
[8.]
U. DiMario, G. Pugliese.
15th Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes.
Diabetologia, 44 (2001), pp. 674-692
[9.]
F. García-Soriano, L. Virág, P. Jagtap, E. Szabó, J.B. Mabley, L. Liaudet, et al.
Diabetic endothelial dysfunction: the roel of poly(ADP-ribose) polymerase activation.
Nature Med, 7 (2001), pp. 108-113
[10.]
R.L. Hopfner, V. Gopalakrishnan.
Endothelin: emerging role in diabetic vascular complicatios.
Diabetologia, 42 (1999), pp. 1383-1394
[11.]
D. Giugliano, A. Ceriello, G. Paolisso.
Oxidative stress and diabetic vascular complications.
Diabetes Care, 19 (1996), pp. 257-267
[12.]
H.H. Ting, F.K. Timimi, K. Boles, S. Creager, P. Ganz, M.A. Creager.
Vitamin C acutely improves endothelium-dependent vasodilation in patients with non-insulin dependent diabetes mellitus.
Circulation, 92 (1995), pp. 1747
[13.]
A.S.D. De Vriese, T.J. Verbeuren, J. Van de Voorde, N.H. Lameire, P.M. Vanhoutte.
Endothelial dysfunction in diabetes.
Br J Pharmacol, 130 (2000), pp. 963-974
[14.]
H. Vlassara.
Recent progress in advanced glycation end products and diabetic complications.
Diabetes, 46 (1997), pp. S19-S25
[15.]
L. Rodríguez-Mañas, J. Angulo, S. Vallejo, C. Peiró, A. Sánchez-Ferrer, E. Cercas, et al.
Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rat vasculature.
Diabetologia, 46 (2003), pp. 556-566
[16.]
L. Rodríguez-Mañas, S. Arribas, C. Girón, J. Villamor, C.F. Sánchez-Ferrer, J. Marín.
Interference of glycosylated human hemoglobin with endothelium-dependent responses.
Circulation, 88 (1993), pp. 2111-2116
[17.]
J. Angulo, C.F. Sánchez-Ferrer, C. Peiró, J. Marín, L. Rodriguez-Mañas.
Impairment of endothelium-dependent relaxation by increasing percentages of glycosylated human hemoglobin. Possible mechanisms involved.
Hypertension, 28 (1996), pp. 583-592
[18.]
S. Vallejo, J. Angulo, C. Peiró, J. Nevado, A. Sánchez-Ferrer, R. Petidier, et al.
Highly glycated oxyhaemoglobin impairs nitric oxide relaxations in human mesenteric microvessels.
Diabetologia, 43 (2000), pp. 83-90
[19.]
J.J. Cartledge, I. Eardley.
Morrison JFB. Impairment of corpus cavernosal smooth muscle relaxation by glycosylated haemoglobin.
BJU Int, 85 (2000), pp. 735-741
[20.]
C.G. Schalkwijk, N. Ligtvoet, H. Twaalfhoven, A. Jager, H.G.T. Blaauwgeers, R.O. Schlingeman, et al.
Amadori albumin in type 1 diabetic patients. Correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries.
Diabetes, 48 (1999), pp. 2446-2453
[21.]
V.M. Monnier, O. Bautista, D. Kenny, D.R. Sell, J. Fogarty, W. Dahms, et al.
Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of Type 1 diabetes. Relevance of glycated collagen products versus HbA1c as markers of diabetic complications.
Diabetes, 48 (1999), pp. 870-880
[22.]
A. Amore, P. Cirina, S. Mitola, L. Peruzzi, B. Gianoglio, I. Rabbone, et al.
Nonenzimatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells.
Kidney Int, 51 (1996), pp. 27-35
[23.]
A. Rojas, S. Romay, D. González, B. Herrera, R. Delgado, K. Otero.
Regulation of endothelial nitric oxide synthase expression by albumin-derived advanced glycosylation end products.
Circ Res, 86 (2000), pp. e50-e4
[24.]
L. Rodríguez-Mañas, J. Angulo, C. Peiró, J.L. Llergo, A. Sánchez-Ferrer, P. López-Dóriga, et al.
Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats.
Br J Pharmacol, 123 (1998), pp. 1495-1502
[25.]
J. Angulo, L. Rodríguez-Mañas, C. Peiró, M. Neira, J. Marín, C.F. Sánchez-Ferrer.
Impairment of nitric oxide-mediated relaxations in anaesthetized autoperfused streptozotocin-induced diabetic rats.
Naunyn-Schmiedeberg's Archives of Pharmacology, 358 (1998), pp. 529-537
[26.]
S. Vallejo, J. Angulo, C. Peiró, A. Sánchez-Ferrer, E. Cercas, J.L. Llergo, et al.
Prevention of endothelial dysfunction in streptozotocin-induced diabetic rats by gliclazide treatment.
J Diabetes Complicat, 14 (2000), pp. 224-233
[27.]
S. Vallejo, J. Angulo, C. Peiró, A. Sánchez-Ferrer, E. Cercas, J. Nevado, et al.
Correction of glycosylated oxyhaemoglobin-induced impairment of endothelium-dependent vasodilatation by gliclazide.
J Diabetes Complicat, 14 (2000), pp. 207-214
[28.]
S. Vallejo, J. Angulo, C. Peiró, E. Cercas, A. Sánchez-Ferrer, J. Nevado, et al.
Treatment with acarbose may improve endothelial dysfunction in streptozotocin-induced diabetic rats.
J Cardiovasc Pharmacol, 36 (2000), pp. 255-262
[29.]
L. Rodríguez-Mañas, P. López-Dóriga, R. Petidier, M. Neira, J. Solís, I. Pavón, et al.
Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes.
J Hypertens, 21 (2003), pp. 1137-1143
[30.]
C. Domínguez, E. Ruiz, M. Gussinye, A. Carrascosa.
Oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents.
Diabetes Care, 21 (1998), pp. 1736-1742
[31.]
J.R. Sowers, M. Epstein.
Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update.
Hypertension, 26 (1995), pp. 869-879
[32.]
J.R. Rumble, M.E. Cooper, T. Soulis, A. Cox, L. Wu, S. Youssef, et al.
Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.
J Clin Invest, 99 (1997), pp. 1016-1027
[33.]
C. Peiró, J. Angulo, L. Rodríguez-Mañas, J.L. Llergo, S. Vallejo, E. Cercas, et al.
Vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin.
Br J Pharmacol, 125 (1998), pp. 637-644
[34.]
C. Peiró, N. Matesanz, J. Nevado, N. Lafuente, E. Cercas, V. Azcutia, et al.
Glycosylated human oxyhaemoglobin activates nuclear factor-kB and activator protein-1 in cultured human aortic smooth muscle.
Br J Pharmacol, 160 (2003), pp. 681-690
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos